Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces
Completion of Patient Enrollment in the Phase II Clinical Trial of Mipsagargin
in Liver Cancer Patients
SAN ANTONIO - October 9, 2014 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for
the treatment of cancer, today announced that patient enrollment has been
completed in the company's Phase II clinical trial in patients with liver
cancer (hepatocellular carcinoma). Formal results of the study are expected to
be available during the first quarter of 2015.
"We
are grateful to the trial investigators for their efforts, as well as the
patients and their loved ones who are supporting this important trial,"
said Craig Dionne, PhD, GenSpera's CEO. "The completion of the enrollment
period for this trial marks another company milestone. The data we have
collected to date establish proof of concept for mipsagargin's destruction of
blood vessels within tumors and encouraging signs of potential anti-tumor
activity. We anticipate similar results in our ongoing Phase II trials in
patients with glioblastoma as well as our planned Phase II trial in patients
with prostate cancer."
Interim data from the ongoing Phase II
clinical trial in liver cancer patients were recently presented at the Asia
Pacific Primary Liver Cancer Expert Meeting in Taipei in July 2014 (APPLE2014)
and at the International Liver Cancer Association (ILCA) meeting in Kyoto in
September 2014. Impressively, 80% of liver cancer patients in the Phase Ib and
Phase II studies experienced disease stabilization at two months and a
significant percentage of patients had stable disease for at least nine months
after beginning treatment with mipsagargin.
The US Food and Drug Administration (FDA)
granted Orphan Drug designation in 2013 for the evaluation of mipsagargin in
patients with hepatocellular carcinoma.
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/10091.asp
About GenSpera
GenSpera's technology platform combines a
powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system
that provides for the targeted release of drug candidates within a tumor.
Unlike typical chemotherapeutic agents, thapsigargin results in cell death
irrespective of the rate of cell division, which may provide an effective
approach to kill both fast- and slow-growing cancers. GenSpera's lead drug
candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high
levels in the vasculature of liver and glioblastoma cancers and in the
vasculature of almost all other solid tumors. Mipsagargin is expected to have
potential efficacy in a wide variety of tumor types.
Mipsagargin Phase II clinical trials are
underway in both hepatocellular carcinoma (liver cancer) and glioblastoma
patients (brain cancer).
For more information, please visit the
company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding
Forward Looking Information
This news release may contain
forward-looking statements. Investors are cautioned that statements in this press
release regarding potential applications of GenSpera's technologies constitute
forward-looking statements that involve risks and uncertainties, including,
without limitation, risks inherent in the development and commercialization of
potential products, uncertainty of clinical trial results or regulatory
approvals or clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements.
Additional information on potential factors that could affect our results and
other risks and uncertainties will be detailed from time to time in GenSpera's
periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Media: Dawn Van Zant
800-665-0411
800-665-0411
Disclaimer/Disclosure: Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure:
Genspera (GNSZ) has engaged Investor Ideas for PR and news publication
effective June 18, 2014 (compensation of five thousand per month and average of
eleven thousand five hundred 144 shares per month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment